These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30143944)

  • 1. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
    Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C
    J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.
    Mattioli F; Stampatori C; Capra R
    Neurol Sci; 2011 Feb; 32(1):83-8. PubMed ID: 20872033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
    Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Rorsman I; Petersen C; Nilsson PC
    Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
    Mattioli F; Stampatori C; Bellomi F; Scarpazza C; Capra R
    PLoS One; 2015; 10(7):e0131803. PubMed ID: 26148120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    Iaffaldano P; Viterbo RG; Trojano M
    J Neurol; 2016 Aug; 263(8):1620-5. PubMed ID: 27260295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
    Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis.
    Iaffaldano P; Ruggieri M; Viterbo RG; Mastrapasqua M; Trojano M
    Brain Behav Immun; 2014 Jan; 35():176-81. PubMed ID: 23994630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
    Wiebenga OT; Schoonheim MM; Hulst HE; Nagtegaal GJ; Strijbis EM; Steenwijk MD; Polman CH; Pouwels PJ; Barkhof F; Geurts JJ
    AJNR Am J Neuroradiol; 2016 Jun; 37(6):1030-7. PubMed ID: 26965463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
    Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
    Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
    Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
    J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.